Braf-Mutant Melanomas: Biology and Therapy

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Melanoma incidence is rising, linked to UV exposure and characterized by high mutational burden.
• BRAF gene mutations, particularly at amino acid 600, are prevalent (40-50%) and critical in melanoma pathogenesis.
• BRAF mutations lead to constitutive MAPK signaling, driving cancer progression.

Purpose of the Study:

• To review the role of BRAF mutations in melanoma.
• To summarize the efficacy of targeted therapies and immunotherapies in BRAF-mutant melanoma.
• To evaluate the impact of neoadjuvant and adjuvant treatment strategies.

Main Methods:

• Literature review of studies on melanoma molecular characterization.
• Analysis of clinical trial data for BRAF inhibitors and immune checkpoint inhibitors (ICIs).
• Comparison of adjuvant vs. neoadjuvant plus adjuvant therapy outcomes.

Main Results:

• BRAF inhibitors and ICIs significantly improve survival in unresectable/metastatic BRAF-mutant melanoma.
• Adjuvant therapy with targeted agents or ICIs improves progression-free survival (PFS) and recurrence-free survival (RFS) in resectable melanoma, but not overall survival (OS).
• Neoadjuvant therapy followed by adjuvant therapy enhances therapeutic response compared to adjuvant therapy alone.

Conclusions:

• Targeted therapy and immunotherapy have transformed BRAF-mutant melanoma treatment.
• Neoadjuvant strategies combined with adjuvant therapy offer improved response rates for resectable melanoma.
• Further research is needed to optimize treatment sequencing and improve long-term outcomes.